3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Nasopharyngeal Carcinoma
5
Nasopharyngeal Neoplasms
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Recurrence
2
Unresectable Non-small Cell Lung Cancer
1
Squamous Non-small Cell Lung Cancer
1
Squamous Non-Small Cell Lung Cancer SqNSCLC
1
Optic Nerve Glioma
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Lymphoma, T-Cell
1
Lung Neoplasms
1
Locally Advanced Squamous Non-small Cell Lung Cancer
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Hepatocellular
1
Advanced Pancreatic Cancer
1
Adenoma, Islet Cell
1
Interventions
Bevacizumab
3
Everolimus
2
tozuleristide
1
neratinib
1
icotinib
1
brigatinib
1
Sirolimus
1
Mn-PyC3A
1
Losartan
1
Lapatinib
1
Fluoresceins
1
Fluorescein
1
Endostatins
1
Axitinib
1
Aspirin
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroma, Acoustic
×
Endostatins
×
Clear all
NCT02104323
2017-02-09
Endostatin
Beijing Tiantan Hospital
Phase 2
Completed
20 enrolled